Publications by authors named "A A Adjei"
Objective: To examine whether youth with ADHD who received a question prompt list and video intervention and their caregivers were more likely to: (a) be asked about their treatment preferences, (b) have their input included into treatment decisions, (c) rate their providers as using more of a participatory decision-making (PDM) style, and (d) be more satisfied with their visits.
Methods: Youth with ADHD were randomized to a pre-visit question prompt list intervention or usual care. Visits were audio-recorded; youth were interviewed after visits; caregivers completed questionnaires.
Background: KO-947, a potent, intravenously administered, extracellular signal-regulated kinase (ERK) inhibitor, has demonstrated activity in preclinical models. This phase I trial of KO-947 evaluated maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with relapsed/refractory solid tumors.
Materials And Methods: This multicenter, open-label, dose-escalation study evaluated KO-947 0.
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT).
Methods: In this single arm multicohort phase I trial, we evaluated the safety and efficacy of ribociclib plus gemcitabine in patients with advanced solid tumors. Patients received gemcitabine intravenously on days 1 and 8 followed by ribociclib days 8-14, with treatment repeated every 3 weeks.
Article Synopsis
- Sickle cell disease (SCD) is a genetic disorder caused by a mutation in the HBB gene, resulting in abnormal hemoglobin S that deforms red blood cells, leading to severe health complications such as pain, anemia, and organ damage.
- The disease is prevalent, especially in sub-Saharan Africa, where over 7.5 million people are affected, often facing underdiagnosis and poor management, particularly in children.
- This study in Ghana aims to identify specific circulating biomarkers in pediatric SCD patients that could help predict disease outcomes and improve patient care by assessing various serum markers associated with inflammation and neuronal injury.
Article Synopsis
- The study highlights that body weight and sex can significantly impact how anticancer drugs are processed in the body, yet the extent of these differences remains unclear.
- A systematic review of 112 studies identified significant pharmacokinetic (PK) differences for 14 out of 99 examined anticancer agents, although no studies currently assess how these differences impact drug efficacy or safety.
- The findings suggest that developing sex-specific dosing strategies for anticancer drugs could improve their risk-benefit ratio for patients.